CDK4/6 inhibitors in endometrial cancer: clinical studies
| NCT0273042965 | NCT0265792866 | NCT0367589367 | |
| Study start date | 15 February 2017 | 08 July 2016 | 24 December 2018 |
| Primary completion date | 15 December 2020 | 21 May 2018 | 01 May 2023 (estimated) |
| Study completion date | 15 December 2021 | 07 October 2020 | 01 May 2025 (estimated) |
| Number of patients | 78 | 20 | 30 |
| Control arm | Letrozole monotherapy | Single-arm | Single-arm |
| Intervention | Palbociclib+letrozole | Ribociclib+letrozole | Abemaciclib+letrozole |
| Median progression-free survival (intervention) | 8.3 months | 5.4 months | 9.1 months |
| Median progression-free survival (control) | 3 months | – | – |
| Reference | Mirza et al, 202013 | Colon-Otero et al, 202011 | Konstantinopoulos et al, 202312 |